A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. by Allen, NE et al.
Allen, NE; Roddam, AW; Allen, DS; Fentiman, IS; Dos Santos Silva,
I; Peto, J; Holly, JMP; Key, TJ (2005) A prospective study of serum
insulin-like growth factor-I (IGF- I), IGF-II, IGF-binding protein-3
and breast cancer risk. British journal of cancer, 92 (7). p. 1283.
ISSN 0007-0920
Downloaded from: http://researchonline.lshtm.ac.uk/13674/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
A prospective study of serum insulin-like growth factor-I (IGF-I),
IGF-II, IGF-binding protein-3 and breast cancer risk
NE Allen1, AW Roddam1, DS Allen2, IS Fentiman2, I dos Santos Silva3, J Peto3,4, JMP Holly5 and TJ Key*,1
1Cancer Research UK Epidemiology Unit, University of Oxford, Radcliffe Inf irmary, Oxford OX2 6HE, UK; 2Academic Oncology Unit, Guy’s Hospital,
London SE1 9RT, UK; 3Department of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E
7HT, UK; 4The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK; 5Division of Surgery, Bristol Royal Inf irmary, Bristol BS2 8HW, UK
The associations between serum concentrations of insulin-like growth factor-I (IGF-I), IGF-II and IGF-binding proteins (IGFBP)-3 and
risk of breast cancer were investigated in a nested case–control study involving 117 cases (70 premenopausal and 47
postmenopausal at blood collection) and 350 matched controls within a cohort of women from the island of Guernsey, UK. Women
using exogenous hormones at the time of blood collection were excluded. Premenopausal women in the top vs bottom third of
serum IGF-I concentration had a nonsignificantly increased risk for breast cancer after adjustment for IGFBP-3 (odds ratio (OR) 1.71;
95% confidence interval (CI): 0.74–3.95; test for linear trend, P¼ 0.21). Serum IGFBP-3 was associated with a reduction in risk in
premenopausal women after adjustment for IGF-I (top third vs the bottom third: OR 0.49; 95% CI: 0.21–1.12, P for trend¼ 0.07).
Neither IGF-I nor IGFBP-3 was associated with risk in postmenopausal women and serum IGF-II concentration was not associated
with risk in pre- or postmenopausal women. These data are compatible with the hypothesis that premenopausal women with a
relatively high circulating concentration of IGF-I and low IGFBP-3 are at an increased risk of developing breast cancer.
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It is well established that insulin-like growth factor-I (IGF-I) and
IGF-II can stimulate cell proliferation and inhibit cell death in
many tissue types (Pollak, 2000) including normal and malignant
breast cancer cells (Sachdev and Yee, 2001). The bioavailability of
circulating IGF ligands is complex; at least six IGF-binding
proteins (IGFBPs) have been identified, the most abundant of
which is IGFBP-3. This binds approximately 75–90% of circulating
IGF-I and IGF-II and may be the most important determinant of
IGF bioavailability (Jones and Clemmons, 1995).
There is considerable between-person variation in the circulat-
ing concentrations of IGF-I, IGF-II and their binding proteins,
believed to be due to genetic and environmental factors (Jones and
Clemmons, 1995; Harrela et al, 1996). This variation may be
important because epidemiological evidence suggests that elevated
levels of serum IGF-I, as absolute concentrations or relative to
IGFBP-3, may be associated with an increased risk of breast cancer
in premenopausal women (Peyrat et al, 1993; Bruning et al, 1995;
Bohlke et al, 1998; Hankinson et al, 1998; Petridou et al, 2000;
Toniolo et al, 2000; Kaaks et al, 2002; Krajcik et al, 2002; Muti et al,
2002; Yu et al, 2002; Keinan-Boker et al, 2003). There are limited
data on the association between serum IGF-II concentration and
breast cancer risk (Holdaway et al, 1999; Li et al, 2001; Yu et al,
2002; Grnbæk et al, 2004).
The aim of this study is to examine the associations between
serum concentrations of IGF-I, IGF-II and IGFBP-3 and subse-
quent breast cancer risk in a case–control study nested within a
cohort of women on the island of Guernsey.
MATERIALS AND METHODS
The Guernsey cohort
Between 1977 and 1991, 6127 women aged 35 years or older who
lived on the British island of Guernsey were recruited into a
prospective study, the main aim of which was to examine the
hormonal determinants of breast cancer risk. Volunteers were
sought through the local media and by using personal contacts and
appeals to local women’s groups. Recruitment was in two phases,
from 1977 to 1985 and from 1986 to 1991; during the second phase
of recruitment, women who had participated in the first phase
were reinvited to the second phase (3680 women participated in
both recruitment phases), and new volunteers were also sought.
Study participants completed a questionnaire at interview contain-
ing details of personal characteristics and reproductive history.
Height and weight measurements were taken and a nonfasting
blood sample was collected. Serum was stored in 2 ml aliquots at
201C until analysis. All participants gave voluntary written
informed consent for the use of their questionnaire data and blood
samples for research purposes.
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Follow-up was through pathology reports (all dealt with by one
pathology laboratory), Guernsey death certificates and the Wessex
cancer registry. A woman was eligible for this study if she was not
using any exogenous sex hormones at the time of blood collection
and if she had not previously been diagnosed with cancer other
than nonmelanoma skin cancer. Women who were premenopausal
at recruitment were eligible if they reported that they were
menstruating in their usual pattern and if their cycle length was
not longer than 42 days. Postmenopausal women were eligible if
they reported that they were naturally postmenopausal at the time
of recruitment (defined as 1 year since their last menstrual period)
or if they had undergone a hysterectomy without bilateral
oophorectomy before menopause and were over 60 years old at
recruitment.
Cases were women diagnosed with breast cancer up until the
end of November 2000. Controls were women who were alive and
free of breast cancer at the time of a case’s diagnosis and who
matched each case according to: age (within 2 years), date of blood
collection (within 1 year) and menopausal status (pre- or
postmenopausal). Cases who stated they were premenopausal at
recruitment were also matched on the day of menstrual cycle
(within 1 day in the category of 1 –29 days until the next menstrual
period and within 2 days in the category of 30þ days).
Postmenopausal cases were matched to controls according to
whether or not they had had a hysterectomy; and, for naturally
postmenopausal cases, the number of years since menopause (1– 2
years or 3þ years). Where it was not possible to match a
postmenopausal case who had had a hysterectomy, controls who
had been naturally postmenopausal for 3 or more years were
identified. Three control subjects were randomly selected from all
those who were suitably matched, except for one premenopausal
case where only two controls were available. Once a control was
matched to a case, she was unavailable for matching with further
cases.
In total, 193 eligible breast cancer cases were identified
during the follow-up period. In all, 76 cases were subsequently
excluded because of insufficient sera, leaving 117 cases (70
premenopausal and 47 postmenopausal) and 350 controls for
analysis (one set had two controls; the remainder had three
controls).
Measurement of serum peptide concentrations
Serum samples for all study participants were shipped on dry
ice to the Division of Surgery, Bristol Royal Infirmary, UK for
measurement of serum IGF-I, IGF-II and IGFBP-3. Individually
matched cases and controls were analysed in the same laboratory
batch and personnel were blinded as to the case–control status of
samples. Double-antibody enzyme-linked immunosorbant (ELISA)
assays were used to measure IGF-I (DSL-10-2800 Active;
Diagnostic Systems Laboratories, Webster, TX, USA) and IGF-II
(DSL-10-2600; Diagnostic Systems Laboratories). Assays for serum
IGFBP-3 were carried out using a previously validated in-house
double antibody radioimmunoassay (Cheetham et al, 1998). Total
coefficients of variation (intra- and interassay combined) were
determined from quality control samples randomly inserted within
each batch; coefficients of variation were 6.6% for IGF-I, 12.0% for
IGF-II and 3.9% for IGFBP3. Although the conditions of blood
collection and the storage temperature were the same in the two
phases of recruitment, the serum from the first phase had been
stored longer and the tubes used for storing serum were different;
therefore, we examined whether there were differences in peptide
concentrations between the two phases of recruitment; among the
control subjects, the medians for IGF-I, IGF-II and IGFBP3 were
21.5, 128 and 173 nmol l1, respectively, for samples from the first
phase of recruitment and 15.7, 131 and 159 nmol l1, respectively,
for samples from the second phase of recruitment. To minimise
the impact of these differences on the estimates of odds ratios
(OR), we categorised women into thirds based on the distribution
among controls in their phase of recruitment.
Statistical analysis
Data for pre- and postmenopausal women were analysed
separately. Comparisons of selected baseline characteristics by
case–control status were examined using the nonparametric
Kruskal–Wallis test for continuous variables and the w2 test for
categorical variables. Age-adjusted Spearman’s correlation coeffi-
cients were used to estimate the correlations between peptide
hormone concentrations in controls. Serum IGF-I, IGF-II and
IGFBP-3 values were categorised into thirds based on the
distribution among the controls in the same phase of recruitment.
The associations between serum peptide concentrations and breast
cancer risk were evaluated using conditional logistic regression
techniques, and relative risks estimated as ORs with their
corresponding 95% confidence intervals (CIs). Adjustment for
the following potential confounding factors was made, in addition
to those controlled for by matching: body mass index (BMI) (o22,
22–23.9, 24– 26.4, 26.5þ kg m2), age at menarche (o14, 14þ
years) and age at first birth (nulliparous,o24, 24–27, 28þ years).
Additional adjustment for IGF-I or IGFBP-3 (included as
categorical variables) was made where appropriate. The associa-
tions of the molar ratios of IGF-I/IGFBP-3 and IGF-II/IGFBP-3
with breast cancer risk were also examined. Odds ratios for each
third were calculated using the lowest third as the reference
category. Where appropriate, a test for linear trend was performed
to assess statistical significance across exposure categories by
scoring each third as 1, 2 and 3. All P-values were based on two-
sided tests; a value of less than 0.05 was considered statistically
significant. The statistical package R was used for all analyses (R
Development Core Team, 2003).
RESULTS
The median time between blood sampling and diagnosis was 13
years for both pre- and postmenopausal women; no cases were
diagnosed within 3 years of recruitment. For women who were
premenopausal at recruitment, the mean age at diagnosis was 57
years; we do not have information on menopausal status at
diagnosis, but the majority of these cases would have been
postmenopausal by the time breast cancer was diagnosed. The
mean age at diagnosis among women who were postmenopausal at
recruitment was 72 years.
Selected baseline characteristics of cases and controls are
presented in Table 1. There were no significant differences in the
median age at recruitment, age at menarche, age at first birth, age
at menopause, height, weight or BMI between cases and controls
among pre- or postmenopausal women. The proportions of
women who were nulliparous, who had ever breast-fed, who had
ever taken exogenous hormones or who were current smokers
were also similar between cases and controls. The median
concentrations of IGF-I, IGF-II and IGFBP-3 did not differ
significantly between cases and controls in either pre- or
postmenopausal women.
The correlations of the three peptide measures with each other
and with other factors were examined in controls. Serum IGF-I was
positively correlated with serum IGF-II (age-adjusted Spearman’s
rank correlation coefficient r¼ 0.32 in premenopausal women and
r¼ 0.47 in postmenopausal women) and with IGFBP-3 (r¼ 0.51 in
premenopausal women and r¼ 0.55 in postmenopausal women).
IGF-II was also strongly positively correlated with IGFBP-3
(r¼ 0.58 in premenopausal women and r¼ 0.62 in postmenopausal
women). IGF-I was inversely related to age, but no significant
associations were found between peptide concentrations and
characteristics such as BMI, smoking, parity, age at menarche,
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age at first birth or age at menopause in either pre- or
postmenopausal women (data not shown).
Table 2 shows the risk of breast cancer associated with
increasing thirds of serum IGF-I, IGF-II and IGFBP-3 in
premenopausal women. Serum IGF-I concentration was not
associated with breast cancer risk, either before or after adjustment
for potential reproductive and other confounders; however, after
statistical adjustment for serum IGFBP-3 concentration, women in
the highest third of IGF-I concentration had an increased risk
compared with women in the lowest third, although this was not
statistically significant (OR 1.71; 95% CI: 0.74– 3.95; test for linear
trend; P¼ 0.21). The association between the molar ratio of IGF-I/
IGFBP-3 and breast cancer risk was similar to that of IGF-I
adjusted for IGFBP-3 (OR 1.61; 95% CI: 0.75–3.47 in the highest vs
the lowest third of IGF-I/IGFBP-3 concentration; test for linear
trend; P¼ 0.19). Serum IGFBP-3 concentration was associated with
a reduction in risk, which was strengthened after statistical
adjustment for BMI, age at menarche and age at first birth (OR
0.60; 95% CI: 0.29– 1.24) for the highest vs the lowest third; test for
linear trend; P¼ 0.02). This association remained but was not
statistically significant after additional statistical adjustment for
serum IGF-I concentration (OR 0.49; 95% CI: 0.21–1.12; test for
linear trend; P¼ 0.07). There was no association between serum
IGF-II concentration and risk in premenopausal women, either
before or after statistical adjustment for IGFBP-3 (Table 2), and no
association was found for the molar ratio of IGF-II/IGFBP-3 (data
not shown).
For postmenopausal women, serum concentrations of IGF-I,
IGF-II and IGFBP-3 were not associated with breast cancer risk
either before or after statistical adjustment for potential con-
founding factors (Table 3).
DISCUSSION
The findings from this small prospective study are consistent with
a moderate increase in breast cancer risk associated with high
levels of IGF-I, after adjustment for IGFBP-3. This is broadly
consistent with previous prospective studies that have found IGF-I,
as absolute concentrations or relative to IGFBP-3, to be predictive
Table 1 Baseline characteristics of breast cancer cases and controls by menopausal statusa
Premenopausal women Postmenopausal women
Cases (n¼70) Controls (n¼209) P-valueb Cases (n¼47) Controls (n¼141) P-valueb
Age at recruitment (years) 41 (37–44) 41 (37–44) 0.83 59 (55–62) 58 (55–63) 0.98
Age at menarche (years) 13 (12–14) 13 (12–14) 0.35 14 (12–15) 13 (12–14) 0.49
Age at first birthc (years) 23 (21–26) 24 (22–27) 0.62 26 (22–29) 25 (23–28) 0.58
Age at menopause (years) N/A N/A 50 (47–52) 50 (48–53) 0.24
Height (cm) 162 (157–165) 161 (157–165) 0.95 158 (155–164) 160 (155–163) 0.52
Weight (kg) 63 (59–69) 62 (56–68) 0.20 62 (58–70) 63 (58–69) 0.96
BMI (kg m2) 24 (23–27) 24 (22–26) 0.16 25 (23–28) 25 (23–27) 0.54
Parity
Nulliparous 6 (9%) 25 (12%) 12 (26%) 20 (14%)
1 8 (11%) 28 (13%) 4 (9%) 28 (20%)
2 35 (50%) 83 (40%) 14 (30%) 36 (26%)
3+ 21(30%) 73 (35%) 0.50 17 (35%) 57 (40%) 0.13
Past OC use
Yes 54 (77%) 152 (73%) 0.47 9 (19%) 27 (19%) 1.00
Past HRT used
Yes N/A N/A N/A 11 (24%) 33 (24%) 0.98
Serum peptides
IGF-I (nmol l1)e 22.4 (18.6–26.9) 22.2 (18.5–26.5) 0.88 16.4 (12.8–23.3) 16.8 (13.5–21.2) 0.86
IGF-II (nmol l1)e 124 (107–144) 129 (114–148) 0.27 125 (111–164) 131 (116–151) 0.63
IGFBP-3 (nmol l1) 170 (141–193) 172 (155–194) 0.10 167 (139–194) 164 (142–194) 0.93
OC¼ oral contraceptive; HRT¼ hormone replacement therapy; IGF¼ insulin-like growth factor; IGFBP¼ IGF-binding proteins; N/A¼ not applicable. aValues are medians
(interquartile range) or numbers (percent). bP-value based on Kruskal –Wallis rank sum test for continuous variables and w2 test for categorical variables. cAmong parous women
only. dData were missing for three postmenopausal women. eSerum IGF-I and IGF-II measurements were unavailable for one premenopausal case.
Table 2 ORs for breast cancer by tertiles of IGF-I, IGF-II and IGFBP-3 for
premenopausal women
Tertile 1 Tertile 2 Tertile 3 P for trend
IGF-I
Number of cases/
controlsa
22/70 22/71 25/68
OR, crudeb 1.00 0.96 (0.49–1.92) 1.20 (0.60–2.37) 0.61
OR, adjustedc 1.00 0.98 (0.49–1.99) 1.19 (0.58–2.46) 0.63
OR, adjustedd 1.00 1.25 (0.58–2.69) 1.71 (0.74–3.95) 0.21
IGF-II
Number of cases/
controlsa
25/70 23/69 21/70
OR, crudeb 1.00 0.92 (0.48–1.77) 0.85 (0.43–1.70) 0.65
OR, adjustedc 1.00 1.02 (0.52–2.01) 0.86 (0.42–1.76) 0.68
OR, adjustedd 1.00 1.27 (0.61–2.64) 1.17 (0.48–2.84) 0.70
IGFBP-3
Number of cases/
controls
32/70 16/69 22/70
OR, crudeb 1.00 0.51 (0.26–1.00) 0.66 (0.33–1.31) 0.19
OR, adjustedc 1.00 0.44 (0.21–0.93) 0.60 (0.29–1.24) 0.02
OR, adjustede 1.00 0.40 (0.19–0.86) 0.49 (0.21–1.12) 0.07
OR¼ odds ratios; IGF¼ insulin-like growth factor; IGFBP¼ IGF-binding proteins;
BMI¼ body mass index. aSerum IGF-I and IGF-II measurements were unavailable for
one premenopausal case. bCrude (matched for age at recruitment, date of blood
collection, day of menstrual cycle). cAdjusted for BMI, age at menarche and age at first
birth. dAdjusted for BMI, age at menarche, age at first birth and IGFBP-3. eAdjusted
for BMI, age at menarche, age at first birth and IGF-I.
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of breast cancer risk in premenopausal women (Hankinson
et al, 1998; Toniolo et al, 2000; Krajcik et al, 2002; Muti et al,
2002), although one study found no association between serum
IGF-I levels and risk in women who were under the age of
50 years at the time of diagnosis (Kaaks et al, 2002). The finding
that serum IGF-I was not associated with breast cancer risk
in postmenopausal women is consistent with data from other
prospective studies (Hankinson et al, 1998; Kaaks et al, 2002;
Krajcik et al, 2002; Toniolo et al, 2000; Keinan-Boker et al, 2003;
Grnbæk et al, 2004).
Our data also show that a relatively high circulating IGFBP-3
concentration is associated with a reduction in risk in pre-, but not
postmenopausal women. Although our findings are consistent with
the nonsignificant inverse association reported in one previous
prospective study (Hankinson et al, 1998), others have found
either no association (Toniolo et al 2000; Kaaks et al, 2002) or an
increased risk with increasing IGFBP-3 concentration in preme-
nopausal women (Toniolo et al, 2000; Krajcik et al, 2002; Muti et al
2002). Nevertheless, our findings are consistent with what is
currently known about the growth-inhibitory properties of IGFBP-
3. It is thought that a relatively high IGFBP-3 concentration may
indirectly reduce cancer risk by binding a greater proportion of
circulating IGF-I, thereby reducing its bioavailability and thus
inhibiting its mitogenic effects (Jones and Clemmons, 1995). In
addition, IGFBP-3 has been shown to directly inhibit cell growth
and induce apoptosis of breast cancer cells independently of its
effect on IGF-I (Oh et al, 1993; Gill et al, 1997).
In this study, adjusting for IGFBP-3 increased the OR for the
association of IGF-I with premenopausal cancers. There is
considerable controversy in the literature regarding measurements
of IGFBP-3. Several commentaries have noted that measurements
of IGFBP-3 are still hampered by technical problems, particularly
in relation to standardisation of assays. It is now evident that there
is considerable heterogeneity in the forms of IGFBP-3. In addition
to major differences in glycosylation and proteolytic modification,
it is clear that there are many other post-translationally modified
forms present in the circulation. The heterogeneity of the protein
presents a considerable challenge for assay calibration. The various
reports of strong and sometimes conflicting associations between
IGFBP-3 concentrations and cancer risk indicate that it would be
of considerable interest to measure individual forms of IGFBP-3.
At present, there are no assays that can reliably measure specific
characterised isoforms of IGFBP-3 and these isoforms can only
really be assessed by electrophoretic techniques that are not easily
applied to epidemiological studies.
Our finding of a lack of association between postmenopausal
circulating levels of IGF-I and IGFBP-3 with subsequent breast
cancer risk, albeit based on only 47 breast cancer cases, are also
consistent with those reported by most other prospective studies,
although the recent study of Grnbæk et al (2004) reported a
positive association between IGFBP-3 and breast cancer risk. The
possible difference in associations of IGF-I and IGFBP-3 and risk
by menopausal status suggests that high levels of IGF-I and/or low
levels of IGFBP-3 may be important in breast cancer development
in younger, but not older, women. If confirmed, the stronger
association of IGF-I with risk in younger than in older women
might be because IGF-I levels are higher, or perhaps because
oestrogen levels are high. IGF-I and IGF-II may be indirectly acting
as an indicator of sex hormone activity in younger women or they
may be directly interacting with oestrogens to increase breast
cancer risk. Indeed, oestradiol has been shown to upregulate
expression of the IGF-I receptor and both hormones can interact in
a synergistic manner to stimulate breast cancer cell proliferation
(Yee and Lee, 2000; Hamelers and Steenbergh, 2003). However,
there are limited epidemiological data on the potential joint effect
of endogenous oestrogens and IGFs on breast cancer risk (Yu et al,
2003), and other, as yet unknown, age-related changes might
influence this association.
This is the first study to examine prospectively the association
between serum IGF-II concentration and breast cancer risk in
premenopausal women. Although IGF-II has a clearly established
role in foetal development (Allan et al, 2001), its function in
postnatal life is less understood, despite circulating at a much
higher concentration than IGF-I. Although experimental evidence
suggests that IGF-II can increase the growth of breast cancer cells
in vitro (Cullen et al, 1992) and is upregulated in many breast
tumours (Li et al, 1998; Fichera et al, 2000), our results show that
circulating IGF-II concentration is not strongly associated with
subsequent breast cancer risk in pre- or postmenopausal women,
which is consistent with evidence from case–control studies
(Holdaway et al, 1999; Li et al, 2001; Yu et al, 2002), although
Grnbæk et al (2004) reported in a prospective study an increase
in risk of breast cancer among postmenopausal women with
increasing IGF-II, which was of borderline statistical significance.
The main strengths of this study are the prospective design with
cases and controls matched according to predefined established
risk factors for breast cancer. In addition, blood samples were
taken at least 3 years before cancer diagnosis, thereby reducing the
possibility that differences in IGF levels are a result of an
undiagnosed breast tumour at the time of blood collection.
Although peptide measurements were made in a single blood
sample from each woman, previous studies suggest that this
reliably reflects long-term IGF-I and IGFBP-3 levels in adult
women, with intraclass correlation coefficients between 0.73 and
0.87 for samples taken a year apart (Kaaks et al, 2000; Borofsky
et al, 2002), and Hunt et al (2002) have reported a Spearman rank
correlation of 0.81 for measures of IGF-II in two samples taken at
different rounds of recruitment. Further, all assay measurements
were conducted blinded and in case–control sets, thereby
minimising the impact of laboratory variation on case– control
comparisons. However, little is known about the correlation
between serum concentrations and bioactive tissue levels.
Although IGFs originate mainly in the liver, they can also be
produced locally in breast cancer cells and can thus act in an
autocrine/paracrine manner as well as through endocrine
pathways (Sachdev and Yee, 2001). Nevertheless, the observation
Table 3 ORs for breast cancer by tertiles of IGF-I, IGF-II and IGFBP-3 for
postmenopausal women
Tertile 1 Tertile 2 Tertile 3 P for trend
IGF-I
Number of cases/
controls
18/48 13/46 16/47
OR, crudea 1.00 0.76 (0.34–1.70) 0.90 (0.42–1.97) 0.80
OR, adjustedb 1.00 0.62 (0.25–1.56) 0.77 (0.34–1.74) 0.56
OR, adjustedc 1.00 0.60 (0.24–1.55) 0.73 (0.29–1.84) 0.52
IGF-II
Number of cases/
controls
20/47 10/47 17/47
OR, crudea 1.00 0.52 (0.22–1.21) 0.83 (0.38–1.83) 0.64
OR, adjustedb 1.00 0.45 (0.19–1.20) 0.87 (0.37–2.05) 0.67
OR, adjustedc 1.00 0.43 (0.17–1.10) 0.81 (0.29–2.28) 0.63
IGFBP-3
Number of cases/
controls
16/47 15/47 16/47
OR, crudea 1.00 0.94 (0.43–2.08) 1.00 (0.43–2.34) 1.00
OR, adjustedb 1.00 0.99 (0.43–2.27) 0.99 (0.40–2.46) 0.98
OR, adjustedd 1.00 1.06 (0.45–2.47) 1.14 (0.40–3.23) 0.81
OR¼ odds ratios; IGF¼ insulin-like growth factor; IGFBP¼ IGF-binding proteins.
aCrude (matched for age at recruitment, date of blood collection, number of years
postmenopausal or hysterectomy). bAdjusted for BMI, age at menarche and age at
first birth. cAdjusted for BMI, age at menarche, age at first birth and IGFBP-3.
dAdjusted for BMI, age at menarche, age at first birth and IGF-I.
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that a reduction in circulating IGF-I can reduce tumour growth in
animals (Dunn et al, 1997; Wu et al, 2003) suggests that blood
levels of IGF-I are biologically meaningful and can serve as an
indicator of the total pool of IGF-I available to cells (Holly and
Hughes, 1994).
In summary, the results of this prospective study are consistent
with the hypothesis that premenopausal women with a relatively
high circulating concentration of IGF-I and low IGFBP-3 are at an
increased risk of developing breast cancer.
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